HALO Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc. (HALO) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 100% planned / 0% discretionary
Largest single sale: $1.7M.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Torley Helen 2 fills | PRESIDENT AND CEO | Sell 10b5-1 | 20,000 | $107.24 | $2.1M | 772,288 −2.5% of holding | |
| Torley Helen 2 fills | PRESIDENT AND CEO | Sell 10b5-1 | 20,000 | $107.17 | $2.1M | 773,192 −2.5% of holding | |
| Torley Helen 3 fills | PRESIDENT AND CEO | Sell 10b5-1 | 20,000 | $107.43 | $2.1M | 774,476 −2.5% of holding | |
| Torley Helen 3 fills | PRESIDENT AND CEO | Sell 10b5-1 | 20,000 | $107.00 | $2.1M | 780,580 −2.5% of holding | |
| Torley Helen 3 fills | PRESIDENT AND CEO | Sell 10b5-1 | 20,000 | $104.18 | $2.1M | 782,077 −2.5% of holding | |
| Torley Helen 5 fills | PRESIDENT AND CEO | Sell 10b5-1 | 20,000 | $102.60 | $2.1M | 786,880 −2.5% of holding | |
| Connaughton Bernadette | Director | Sell 10b5-1 | 1,626 | $102.80 | $167.2K | 40,418 −3.9% of holding | |
| Torley Helen 2 fills | PRESIDENT AND CEO | Sell 10b5-1 | 1,923 | $79.77 | $153.4K | 768,815 −0.2% of holding | |
| Connaughton Bernadette 2 fills | Director | Sell 10b5-1 | 1,625 | $76.71 | $124.7K | 42,669 −3.7% of holding | |
| Krishnan Mahesh | Director | Sell 10b5-1 | 7,304 | $75.00 | $547.8K | 14,462 −33.6% of holding | |
| Torley Helen 4 fills | PRESIDENT AND CEO | Sell 10b5-1 | 10,000 | $69.07 | $690.7K | 777,380 −1.3% of holding | |
| Torley Helen 2 fills | PRESIDENT AND CEO | Sell 10b5-1 | 20,000 | $66.39 | $1.3M | 771,180 −2.5% of holding | |
| Torley Helen 3 fills | PRESIDENT AND CEO | Sell 10b5-1 | 20,000 | $67.58 | $1.4M | 786,170 −2.5% of holding | |
| Connaughton Bernadette | Director | Sell 10b5-1 | 1,625 | $66.21 | $107.6K | 43,669 −3.6% of holding | |
| Torley Helen 4 fills | PRESIDENT AND CEO | Sell 10b5-1 | 10,000 | $69.19 | $691.9K | 775,680 −1.3% of holding | |
| Torley Helen 5 fills | PRESIDENT AND CEO | Sell 10b5-1 | 20,000 | $71.75 | $1.4M | 787,680 −2.5% of holding | |
| Torley Helen 3 fills | PRESIDENT AND CEO | Sell 10b5-1 | 20,000 | $65.35 | $1.3M | 778,055 −2.5% of holding | |
| Connaughton Bernadette | Director | Sell 10b5-1 | 1,625 | $63.48 | $103.2K | 38,498 −4.1% of holding | |
| Torley Helen 2 fills | PRESIDENT AND CEO | Sell 10b5-1 | 10,000 | $63.50 | $635.0K | 771,880 −1.3% of holding | |
| Torley Helen 2 fills | PRESIDENT AND CEO | Sell 10b5-1 | 20,000 | $64.24 | $1.3M | 771,980 −2.5% of holding | |
| Torley Helen 2 fills | PRESIDENT AND CEO | Sell 10b5-1 | 20,000 | $65.38 | $1.3M | 768,780 −2.5% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.